全文获取类型
收费全文 | 440篇 |
免费 | 27篇 |
国内免费 | 26篇 |
出版年
2023年 | 13篇 |
2022年 | 17篇 |
2021年 | 26篇 |
2020年 | 19篇 |
2019年 | 19篇 |
2018年 | 16篇 |
2017年 | 13篇 |
2016年 | 11篇 |
2015年 | 11篇 |
2014年 | 30篇 |
2013年 | 24篇 |
2012年 | 10篇 |
2011年 | 27篇 |
2010年 | 14篇 |
2009年 | 24篇 |
2008年 | 32篇 |
2007年 | 26篇 |
2006年 | 23篇 |
2005年 | 26篇 |
2004年 | 19篇 |
2003年 | 19篇 |
2002年 | 10篇 |
2001年 | 16篇 |
2000年 | 10篇 |
1999年 | 5篇 |
1998年 | 4篇 |
1997年 | 8篇 |
1996年 | 7篇 |
1995年 | 4篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1990年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有493条查询结果,搜索用时 46 毫秒
1.
2.
3.
Michel Adamina Reto Schumacher Paul Zajac Walter P. Weber Rachel Rosenthal Célia Groeper 《Journal of liposome research》2013,23(3):195-204
Malignant tumors represent a major source of disability and account for more than one of five deaths in Western countries. Among the different cancers, melanoma harbors two distinctive features. First, its has long been recognized as an immunogenic tumor, and second, an unprecedented rise in incidence is currently observed, in face of few therapeutic options. Thus, melanoma represent an ideal target for a cancer immunotherapy program. To date, a number of immunodominant epitopes from tumor associated antigens (TAA) are used as cancer vaccines in clinical trials, in spite of an acknowledged rapid degradation in vivo and low immunogenicity. However, most of the immunotherapy trials reported so far do not achieve consistent clinical results. Hence, there is an urgent need for the development of a carrier system and strong adjuvants suitable for a TAA-based cancer immunotherapy. Liposomes and their further development as virosomes with added adjuvancy may address both these issues. We report here our experience in the tailoring of dedicated advanced liposomal vectors that were developed in the context of an upcoming immunotherapy clinical trial for melanoma. 相似文献
4.
黏膜是阻止病原入侵的第一道防线,黏膜免疫系统在抵抗感染方面起着至关重要的作用。通过黏膜途径接种疫苗可以同时诱导黏膜和全身免疫反应,因此,理论上针对黏膜的免疫策略是最合理和有效的。但黏膜免疫系统的复杂性和屏障作用造成抗原诱导的免疫应答水平低下,制约了黏膜疫苗的发展。M细胞(Microfoldcells)是黏膜免疫系统所独有的,其具有捕获腔内抗原和启动抗原特异性免疫应答的功能。M细胞摄取抗原的多少直接关系到黏膜疫苗的免疫效力,而利用M细胞配体可将抗原靶向递呈给M细胞,从而实现高效的黏膜免疫应答。靶向M细胞的抗原递送策略及其应用可以提高黏膜免疫应答水平,促进黏膜疫苗的研制。尽管如此,要成功研制安全高效的黏膜疫苗,今后依然有漫长的路要走,这可能有赖于进一步探究M细胞的特性和功能及黏膜免疫机制。 相似文献
5.
A.C.F.B. Ajorio V.P. Rhodes A.P. Rodrigues V.A. Diniz J.M.V. Mattoso I.B. da Silva D.M.M. D`Aiuto M.L.L. Brandão 《Letters in applied microbiology》2022,74(4):536-542
This study aimed to evaluate the performance of hydrogen peroxide vapour (HPV) to inactivate the chimpanzee adenovirus AZD1222 vaccine strain used in the production of recombinant COVID-19 vaccine for application in cleaning validation in pharmaceutical industries production areas. Two matrixes were tested: formulated recombinant COVID-19 vaccine (FCV) and active pharmaceutical ingredient (API). The samples were dried on stainless steel and exposed to HPV in an isolator. One biological indicator with population >106 Geobacillus stearothermophilus spores was used to validate the HPV decontamination cycle as standard. HPV exposure resulted in complete virus inactivation in FVC (≥5·03 log10) and API (≥6·40 log10), showing HPV efficacy for reducing chimpanzee adenovirus AZD1222 vaccine strain. However, the optimum concentration and contact time will vary depending on the type of application. Future decontamination studies scaling up the process to the recombinant COVID-19 vaccine manufacturing areas are necessary to evaluate if the HPV will have the same or better virucidal effectivity in each specific production area. In conclusion, HPV showed efficacy for reducing AZD1222 chimpanzee adenovirus strain and can be a good choice for pharmaceutical industries facilities disinfection during recombinant COVID-19 vaccine production. 相似文献
6.
Reinaldo de Menezes Martins Cristina de Albuquerque Possas Akira Homma 《Memórias do Instituto Oswaldo Cruz》2015,110(1):114-124
This paper presents, from the perspective of technological development and
production, the results of an investigation examining 61 clinical studies with
vaccines conducted in Brazil between 1938-2013, with the participation of the Oswaldo
Cruz Institute (IOC) and the Oswaldo Cruz Foundation (Fiocruz). These studies have
been identified and reviewed according to criteria, such as the kind of vaccine
(viral, bacterial, parasitic), their rationale, design and methodological strategies.
The results indicate that IOC and Fiocruz have accumulated along this time
significant knowledge and experience for the performance of studies in all clinical
phases and are prepared for the development of new vaccines products and processes.
We recommend national policy strategies to overcome existing regulatory and financing
constraints. 相似文献
7.
Early‐shared Mycobacterium bovis bacillus Calmette–Guérin sub‐strains induce Th1 cytokine production in vivo 下载免费PDF全文
Keiichi Taniguchi Yuuji Miyatake Daisuke Hayashi Atsuro Takami Saotomo Itoh Saburo Yamamoto Shigeaki Hida Kikuo Onozaki Takemasa Takii 《Microbiology and immunology》2015,59(11):684-689
8.
9.
冠状病毒是一类可感染人类和动物的RNA病毒,可引起严重急性呼吸综合征(SARS)和中东呼吸综合征(MERS)等严重疾病。新型冠状病毒是以前从未在人体中发现的冠状病毒新毒株,其人际传播迅速,引起了各国政府的高度重视并积极寻求疫苗防控对策。基于冠状病毒疫苗领域全景专利,在综合对比分析该领域的全部专利的发展趋势、主要国家和主要机构的专利产出的同时,重点揭示了其中的人用相关疫苗的发展与分布情况以及重点分析了人用疫苗产品的研发现状,以期为我国冠状病毒疫苗领域的科研工作者和管理决策者提供参考数据。 相似文献
10.